I always wonder how it is possible that, in the event of a conversion of the bonds at a discount compared to the market value, they are sold immediately, content with a 20% profit, considering that the company is probably worth much more..... But trying objectively to see reality, unfortunately, now, Gnbt does not have concrete results, real data that can support what the company has declared.
The result of the peptide tests could "open the eyes" of many and finally give credibility to the words of Moscato and Purcell. And the start of phase 1 with human trials should follow closely. For now they are, in the eyes of the financial community, just fine words with no concrete evidence: perhaps for this reason, bondholders who convert prefer to sell immediately and settle for a small gain ..
Unfortunately, the months pass and we are always at the stake, while others run: this situation creates further mistrust, and everything affects the pps, blocked at 20 cents. More than ever we need "numbers" that confirm the goodness of the li-key vaccine.